Molecular Therapeutics The Molecular Therapeutics Program seeks to integrate basic and translational science to develop novel therapeutic agents and clinical trials that have strong scientific rationales. The program weaves together workers in four broad areas related to molecular approaches to cancer therapy: oncogenic signaling, structural biology, pharmacology and pharmacogenetics and drug discovery and delivery. For example, structural biologists combine with medicinal chemists in our small molecule drug discovery effort, who then work with animal models experts to test these agents. These same models are used by our physical scientists to test novel therapeutic approaches with the help of our pharmacologists who study these delivery and efficacy of these new therapeutics. Research by program members has resulted in exciting findings, among which are innovative nanodelivery approaches, novel carbon-nanotube x-ray sources, new biomarkers of therapeutic toxicity, and enhanced understanding and modeling of cancer signaling pathways. The program adds value to the center by bringing physicists, chemists, mouse geneticists, biologists, pharmacologists, and clinical and translational researchers together to participate in new drug discovery, the elucidation of mechanisms of action of therapeutically relevant compounds, and innovative clinical trials. Pilot funding to push promising therapeutic modalities forward is provided as is attention to movement into the clinic and commercialization. The 42 program members come from seven departments from three schools: Medicine, Pharmacy, and College of Arts and Sciences. Members are major participants in 4 program project grants. Total cost funding in 2009 was $31.7 million including $9.6 million in NCI funding. Members generated 1,120 publications over the past six years, of which -8% were intraprogrammatic and 21% were interprogrammatic. Dr. Gary Johnson, program co-leader for the last 7 years, is the Chair of Pharmacology and is renowned for his research defining MAPK signal transduction pathways and their biologic significance. Dr. Norman Sharpless, program co-leader for the last 2 years, is a clinically active physician-scientist with a national reputation in translational research with particular expertise in murine cancer models. Through strategic recruitment and the Molecular Therapeutics Program has significantly increased in size over the prior period of funding. The program is poised to expand efforts to develop innovative therapeutic drugs, diagnostics and devices for patients with cancer and test them in concert with the Clinical Research and Breast Cancer Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594127
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$151,904
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Dunn, Julia L M; Kartchner, Laurel B; Gast, Karli et al. (2018) Mammalian target of rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury. J Leukoc Biol 103:909-918
Kolupaev, Oleg V; Dant, Trisha A; Bommiasamy, Hemamalini et al. (2018) Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Adv 2:2307-2319
Beckford Vera, Denis R; Smith, Christof C; Bixby, Lisa M et al. (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13:e0193832
McLamarrah, Tiffany A; Buster, Daniel W; Galletta, Brian J et al. (2018) An ordered pattern of Ana2 phosphorylation by Plk4 is required for centriole assembly. J Cell Biol 217:1217-1231
Sanoff, Hanna K (2018) Best Evidence Supports Annual Surveillance for Resected Colorectal Cancer. JAMA 319:2083-2085
Chiou, Yi-Ying; Hu, Jinchuan; Sancar, Aziz et al. (2018) RNA polymerase II is released from the DNA template during transcription-coupled repair in mammalian cells. J Biol Chem 293:2476-2486
Kwo, Paul; Fried, Michael W; Reddy, K Rajender et al. (2018) Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun 2:354-363
Dunn, Julia L M; Kartchner, Laurel B; Stepp, Wesley H et al. (2018) Blocking CXCL1-dependent neutrophil recruitment prevents immune damage and reduces pulmonary bacterial infection after inhalation injury. Am J Physiol Lung Cell Mol Physiol 314:L822-L834
Xiao, Weidong; Gao, Guangping; Ling, Chen et al. (2018) Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nat Med 24:699
Zhang, Xintao; He, Ting; Chai, Zheng et al. (2018) Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176:71-83

Showing the most recent 10 out of 1525 publications